Trial Profile
Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Tafasitamab (Primary) ; Lenalidomide
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 24 Feb 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 24 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.
- 07 Sep 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.